Trial Profile

A Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-finding Phase 2b Clinical Trial to Evaluate the Efficacy and Safety of URC102 in Patient With Gout

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 16 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs URC 102 (Primary)
Indications Gout
Focus Therapeutic Use
Sponsors JW Pharmaceutical

Most Recent Events

26 May 2025 Primary endpoint (proportion of patients with sUA level 0.36 mmol/L at week 4 after initiation of study treatment) has been met as per results published in the Arthritis Research and Therapy
26 May 2025 Results published in the Arthritis Research and Therapy
16 Mar 2021 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com